Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01404897
Other study ID # MM3274
Secondary ID
Status Completed
Phase N/A
First received July 22, 2011
Last updated March 25, 2015
Start date July 2011
Est. completion date December 2013

Study information

Verified date March 2015
Source Children's Hospital & Research Center Oakland
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The Dietary Approaches to Stop Hypertension (DASH) trial has been shown to reduce blood pressure and plasma total and LDL-cholesterol (C) compared to a Western diet, but shows no benefit on other blood lipid variables associated with cardiovascular disease (CVD) risk, namely HDL-cholesterol and triglycerides. The overall objective of this study is to determine whether modification of the DASH diet by substituting carbohydrate with fat will result in improvements in multiple biomarkers of CVD risk. Specifically, the investigators will test the hypotheses that modification of the DASH diet by reducing carbohydrate, primarily in the form of simple sugars and glycemic starches, and allowing for a more liberal intake of total and saturated fat, primarily from dairy foods, will: (1) improve lipoprotein markers of CVD risk (reduced total/HDL-C ratio, apolipoprotein B, small LDL particles, and increased HDL-C, apoAI, and large HDL particles); and (2) result in comparable reductions of systolic and diastolic blood pressure to those achieved with the standard DASH diet. The investigators will also assess the effects of the modified DASH diet on markers of insulin resistance and inflammation. Our main hypotheses will be tested by a controlled dietary intervention conducted in 40 healthy men and women who will be randomly allocated to consume, for 3 weeks each, a control Western diet, a standard DASH diet, and a modified low-carbohydrate DASH diet, separated by 2-week washout periods.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 22 Years and older
Eligibility Inclusion Criteria:

- Age 22 years and older

- Average systolic blood pressure <160 mm Hg and diastolic blood pressure 80 - 95 mm Hg measured on 2 separate days

- Non-smoking

- Agrees to abstain from alcohol and dietary supplements during the study

- Willing to consume all study foods as instructed

Exclusion Criteria:

- History of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or cancer (other than skin cancer) in the last 5 years.

- Taking hormones or drugs known to affect lipid metabolism or blood pressure.

- Body Mass Index (BMI) > 35

- Total- and LDL-cholesterol > 95th percentile for sex and age.

- Fasting triglycerides > 500 mg/dl.

- Fasting blood sugar (FBS) > 126 mg/dl.

- Abnormal thyroid stimulating hormone

- Not weight stable

- Pregnant or breast-feeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Other:
Dietary Intervention
3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
Dietary Intervention
3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
Dietary Intervention
3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.

Locations

Country Name City State
United States Cholesterol Research Center, Children's Hospital Oakland Research Institute Berkeley California

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital & Research Center Oakland Dairy Management Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total:HDL-cholesterol ratio 4 weeks No
Primary HDL-cholesterol 4 weeks No
Primary Apolipoprotein B 4 weeks No
Primary Apolipoprotein AI 4 weeks No
Primary Small LDL particles 4 weeks No
Primary Large HDL particles 4 weeks No
Primary Total:HDL-cholesterol ratio 9 weeks No
Primary Total:HDL-cholesterol ratio 14 weeks No
Primary HDL-cholesterol 9 weeks No
Primary HDL-cholesterol 14 weeks No
Primary Apolipoprotein B 9 weeks No
Primary Apolipoprotein B 14 weeks No
Primary Apolipoprotein AI 9 weeks No
Primary Apolipoprotein AI 14 weeks No
Primary Small LDL particles 9 weeks No
Primary Small LDL particles 14 weeks No
Primary Large HDL particles 9 weeks No
Primary Large HDL particles 14 weeks No
Secondary Blood Pressure End of each experimental diet (4 wks, 9 wks, and 14 wks) No
Secondary Triglycerides End of each experimental diet (4 wks, 9 wks, and 14 wks) No
Secondary Total Cholesterol End of each experimental diet (4 wks, 9 wks, and 14 wks) No
Secondary LDL-Cholesterol End of each experimental diet (4 wks, 9 wks, and 14 wks) No
Secondary Lipoprotein Subclasses (HDL, LDL, IDL, VLDL) End of each experimental diet (4 wks, 9 wks, and 14 wks) No
Secondary HOMA-IR End of each experimental diet (4 wks, 9 wks, and 14 wks) No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment